New pill shows promise against advanced cancers in early trial

NCT ID NCT03449381

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor taken as a tablet, either once every 3 weeks or on two days every 4 weeks. Participants stayed in the study as long as they benefited and tolerated the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brigimadlin (BI 907828)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early phase 1 trial, so the main goal is just to find a safe dose. It is too soon to know if brigimadlin will actually shrink tumors or improve survival, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer gastric adenocarcinoma neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium
Florida Cancer Specialists-Sarasota-61670

Sarasota, Florida, 34232, United States
Fundación Jiménez Díaz

Madrid, 28040, Spain
Helios Klinikum Berlin-Buch

Berlin, 13125, Germany
Hospital Clínic de Barcelona

Barcelona, 08036, Spain
Hospital Clínico de Santiago

Santiago de Compostela, 15706, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Karolinska Comprehensive Cancer Center

Stockholm, 171 76, Sweden
MED POLONIA SP Z O O, Clinical Trials Department,Poznan

Poznan, 60-693, Poland
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center Hospital

Tokyo, Chuo-ku, 104-0045, Japan
Norton Cancer Institute, Downtown

Louisville, Kentucky, 40202, United States
Oncology Center-Maria Sklodowska-Curie Institute

Warsaw, 02-781, Poland
Rigshospitalet, København

København Ø, 2100, Denmark
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
Sarcoma Oncology Center

Santa Monica, California, 90403, United States
Severance Hospital

Seoul, 03722, South Korea
Sourasky Medical Center

Tel Aviv, 6423906, Israel
The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UZ Leuven

Leuven, 3000, Belgium
University of Wisconsin

Madison, Wisconsin, 53792, United States
Universitätsklinikum Köln (AöR)

Cologne, 50937, Germany
Universitätsklinikum Tübingen

Tübingen, 72076, Germany
Universitätsmedizin Göttingen, Georg-August-Universität

Göttingen, 37075, Germany
Yale University School of Medicine

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.